Literature DB >> 12195616

Electronic case-report forms of symptoms and impairments of peripheral neuropathy.

Peter J Dyck1, David W Turner, Jenny L Davies, Peter C O'Brien, P James B Dyck, Cynthia A Rask.   

Abstract

BACKGROUND AND
OBJECTIVE: For the conduct of controlled clinical trials, epidemiologic surveys or even of medical practice of varieties of peripheral neuropathy, the usefulness, error rate and cost-effectiveness of scannable case-report forms has not been studied.
MATERIALS AND METHODS: The overall performance, the frequency of the problems identified and corrected, and the time saved from use of a standard paper case report form was evaluated in multicenter treatment trials, single center epidemiologic surveys and in our neurologic practice. The paper case report form (Clinical Neuropathy Assessment [CNA]) for pen entry at study medical centers for patient, disease and demographic information (Lower Limb Function [LLF] and Neuropathy Impairment Score [NIS]) can be faxed to a core Reading and Quality Assurance Center where the form and data is electronically and interactively evaluated and corrected, if needed, by participating medical centers before electronic entry into database. OBSERVATIONS AND
CONCLUSIONS: 1) The approach provides a standard, scannable paper case report form for pen entry of neuropathy symptoms, impairments and disability at the bedside or in the office which is retained as a source document at the participating medical center but a facsimile can be transferred instantaneously, its data can be programmed, interactively evaluated, modified and stored while maintaining an audit trail; 2) it allowed efficient and accurate reading, transfer, analysis, and storage of data of more than 15,000 forms used in multicenter trials; 3) in 500 consecutive CNA evaluations, software programs identified and facilitated interactive corrections of omissions, discrepancies, and disease and study inconsistencies, introducing only a few readily identified and corrected entry errors; and 4) use of programmed, as compared to non-programmed assessment, was more accurate than double keyboard entry of data and was approximately five times faster.

Entities:  

Mesh:

Year:  2002        PMID: 12195616     DOI: 10.1017/s0317167100002043

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  10 in total

1.  Reducing errors from the electronic transcription of data collected on paper forms: a research data case study.

Authors:  Monika M Wahi; David V Parks; Robert C Skeate; Steven B Goldin
Journal:  J Am Med Inform Assoc       Date:  2008-02-28       Impact factor: 4.497

2.  Longitudinal study of intraneural perineurioma--a benign, focal hypertrophic neuropathy of youth.

Authors:  Michelle L Mauermann; Kimberly K Amrami; Nancy L Kuntz; Robert J Spinner; Peter J Dyck; E Peter Bosch; Janean Engelstad; Joel P Felmlee; P James B Dyck
Journal:  Brain       Date:  2009-06-30       Impact factor: 13.501

Review 3.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

4.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

5.  Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J J Figueroa; P J B Dyck; R S Laughlin; J A Mercado; R Massie; P Sandroni; P J Dyck; P A Low
Journal:  Neurology       Date:  2012-02-22       Impact factor: 9.910

6.  MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families.

Authors:  Geir J Braathen; Jette C Sand; Ana Lobato; Helle Høyer; Michael B Russell
Journal:  BMC Med Genet       Date:  2010-03-29       Impact factor: 2.103

7.  Two novel missense mutations in the myelin protein zero gene causes Charcot-Marie-Tooth type 2 and Déjérine-Sottas syndrome.

Authors:  Geir J Braathen; Jette C Sand; Michael B Russell
Journal:  BMC Res Notes       Date:  2010-04-12

8.  Comparative Assessment of the Activity of Racemic and Dextrorotatory Forms of Thioctic (Alpha-Lipoic) Acid in Low Back Pain: Preclinical Results and Clinical Evidences From an Open Randomized Trial.

Authors:  Alessandra Pacini; Daniele Tomassoni; Elena Trallori; Laura Micheli; Francesco Amenta; Carla Ghelardini; Lorenzo Di Cesare Mannelli; Enea Traini
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

9.  Variants in the genes DCTN2, DNAH10, LRIG3, and MYO1A are associated with intermediate Charcot-Marie-Tooth disease in a Norwegian family.

Authors:  G J Braathen; H Høyer; Ø L Busk; K Tveten; C F Skjelbred; M B Russell
Journal:  Acta Neurol Scand       Date:  2015-10-12       Impact factor: 3.209

10.  Clinical characteristics and proteome modifications in two Charcot-Marie-Tooth families with the AARS1 Arg326Trp mutation.

Authors:  Geir J Braathen; Hilde L Nilsen; Helle Høyer; Øyvind L Busk; Q Ying Esbensen; Oddveig Røsby; Hilde T Hilmarsen; Michael B Russell; Tuula A Nyman
Journal:  BMC Neurol       Date:  2022-08-15       Impact factor: 2.903

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.